SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a significant private placement announcement and a strategic investment related to launching a Worldcoin treasury strategy, sparking a massive pre-market surge and short squeeze. The community is actively discussing the potential for further gains, with some drawing comparisons to other high-flying stocks and speculating on how high it can go, while others caution about potential dilution risks. News of Dan Ives joining as Chairman seems to be adding fuel to the fire.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending due to a mix of factors, including recent news of SpaceX acquiring spectrum, sparking concerns about increased competition, and the overall volatility in space stocks. The community is debating whether this validates ASTS's technology or poses a significant challenge. Bullish investors view it as a buying opportunity, while bears express concerns about dilution and the company's ability to compete.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after a live demo of its solid-state batteries powering a Ducati motorcycle at the IAA Mobility event, sparking enthusiasm among investors. The community is buzzing about the potential for the technology in EVs and motorcycles, along with possible partnerships with major automotive manufacturers. Despite a long timeline to commercialization, some believe the demonstration validates the long-term potential of solid-state battery technology.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as it joins the S&P 500, replacing Caesars Entertainment, which has sparked enthusiasm and predictions of significant inflows from index funds. While some traders are wary of a potential "sell the news" event, others anticipate further gains fueled by the upcoming company summit and potential rate cuts. Community members are actively discussing potential price targets and the impact of index inclusion on the stock's long-term value.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors discuss its potential S&P 500 inclusion, with community members analyzing technical levels and anticipating a breakout. Bullish sentiment is fueled by the company's strong performance and perceived undervaluation compared to peers. Some traders express caution, citing potential overvaluation and historical patterns after index additions.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid speculation surrounding a potential Dogecoin ETF, with the community buzzing about possible approval and its impact. Some traders point to technical indicators suggesting bullish momentum, while others are discussing the potential for Dogecoin to reach new all-time highs. The conversation also includes debate around Dogecoin's utility and its future in the broader crypto market.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics (MCRB) is trending amid rumors of a potential acquisition by Nestle, with community members closely watching for confirmation and speculating on the details of the offer, including milestone payments. The company's conference presentation is also generating buzz, as investors hope for updates on potential deals. A potential short squeeze is also part of the discussion due to the ticker's high short interest.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending due to strong Q2 FY2026 earnings, including record revenue and positive adjusted EBITDA, leading to raised full-year guidance. The community is actively discussing the significant increase in backlog and remaining performance obligations, viewing it as a sign of strong sales execution. Despite the positive news, some traders are questioning why the stock is not performing better, while others are optimistic about a potential rerating and further gains.

Hour Loop, Inc. is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market and sell products. It operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company was founded by Sam Lai and Sau Kuen Yu in 2013 and is headquartered in Redmond, WA.

Hour Loop Inc

HOUR is trending due to significant volatility, marked by rapid price swings and trading halts, leading to community discussions about potential pump-and-dump schemes and coordinated efforts. Traders are actively debating entry and exit strategies amidst the stock's high volume and low float, while some express concerns about the lack of news driving the movement. The stock's behavior is also being compared to other recent low float runners.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to its strategic investment in Talphera (TLPH) for Niyad, a potential CRRT treatment, sparking discussions about a possible acquisition and future roll-up company strategy. Community members are weighing the risks and potential rewards, including possible buy-out scenarios, while some express reservations about the company's expanding ventures and the impact of the Melinta deal. Bullish sentiment remains, with some eyeing a potential institutional influx and a climb towards higher valuations amid discussions on financial guidance and sales estimates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Analyst Reports for Microsoft, Amazon.com & Philip Morris

Microsoft, Amazon.com and Philip Morris headline fresh analyst reports highlighting AI, cloud, and smoke-free growth momentum.

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

Electromed traded higher after hours on Tuesday as management highlighted hospital market share gains from a “distracted rival”, a strategy they credited with contributing to the company’s 11th straight quarter of year-over-year revenue and profit growth.The stock closed up 2.3% at $20.66 on Tuesday and jumped another 12.6% after hours following its earnings release.The maker of the SmartVest airway clearance system reported record fourth-quarter revenue of $17.4 million, up 17% from last year, as profit rose 21% to $2.2 million, or $0.25 a share.&nbsp;On the earnings call, Electromed detailed growth drivers beyond the headline numbers. Executives said hospitals are proving to be a “gateway” channel as patients introduced to SmartVest in care settings are often discharged with prescriptions for home use.&nbsp;CEO Jim Cunniff added that a major competitor with an “older product” is internally distracted, creating opportunities for market share growth.The company also highlighted strong e-prescribe adoption, with 38% of orders now submitted digitally, resulting in a halving of&nbsp;fulfillment times. A new Salesforce-based CRM integrating sales and reimbursement teams has also been rolled out, earning positive early feedback.&nbsp;Productivity gains continue, with sales&nbsp;representatives averaging $1.06 million each in annual revenue, up from $850,000 three years ago. Expansion to 61 territories is planned for FY26.Electromed is also benefiting from greater awareness of bronchiectasis after Insmed’s new drug launch, which executives said is raising disease visibility without competing on airway clearance.&nbsp;Earlier this month, the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved Insmed’s Brinsupri</a>, an oral once-daily treatment, as the first and only FDA-approved therapy for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The drug is cleared for use in adults and children aged 12 and older.&nbsp;Electromed noted over 31,000 visits to its bronchiectasis campaign site and cited registry data showing 58% of patients meeting criteria for HFCWO therapy remain untreated, a gap it sees as a major market opportunity.On Stocktwits, retail sentiment for Electromed was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/ELMD">Electromed’s stock</a> has declined over 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Electromed’s stock (ELMD) has declined over 30% so far in 2025. (Photo credit: Getty Images)

Why Electromed Stock Jumped 12% After-Hours: A Rival’s Weakness And A New Drug Tailwind

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Equity

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the shares after the firm’s Brinsupri got approved as a treatment for non-cystic fibrosis bronchiectasis (NCFB).The new price target of $240 represents a near 97% upside to INSM’s closing price on Tuesday.H.C. Wainwright sees Insmed as "poised to join the ranks" of Roche's (RHHBY) Genentech and Pfizer's (PFE) Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy, said the analyst. Wainwright believes that Brinsupri and its next-generation versions will be able to treat a broad range of neutrophil-mediated diseases.Given the approval and potential for a "pipeline-in-a-pill", the firm now includes chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS) indications in its valuation, assuming a launch by 2027 for CRSsNP and a launch by 2028 for HS.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INSM">Insmed</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1252/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_1_21_34_PM_png_eb547ea1d1.webp" alt="INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="1252" height="120"><figcaption>INSM's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the shares to hit $150 by the end of the week.<stembedurl>https://stocktwits.com/king9885/message/624942721</stembedurl>Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for NCFB. It was <a href="https://stocktwits.com/news-articles/markets/equity/insmed-announces-fda-approval-for-drug-to-treat-chronic-lung-disease/chrxJPSRdJk">approved</a> on Tuesday for adults as well as children aged 12 years and older.Bronchiectasis is a serious, chronic lung disease that causes airways to permanently widen due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. A hallmark of bronchiectasis is frequent exacerbations, or flares, when symptoms worsen.In a late-stage study, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also significantly prolonged the time to first exacerbation.INSM stock is up by 76% this year and by 59% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reshape-lifesciences-stock-rockets/chrC0AtRd9N">ReShape Lifesciences Stock Rocketed 61% Today – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment approved for non-cystic fibrosis bronchiectasis (NCFB).&nbsp;The stock jumped 8.1% on Tuesday, closing at&nbsp;its highest level in nearly 25 years before slipping 0.6% in after-hours trading.The once-a-day oral medicine is approved for adults and children 12 and older, offering a new option for patients with a condition that has had no dedicated therapies until now.NCFB is a long-term lung disease that causes permanent widening of the airways, driven by a cycle of infection, inflammation, and tissue damage. Symptoms include chronic cough,&nbsp;excessive mucus production, shortness of breath, and frequent infections, which can lead to exacerbations.&nbsp;In the U.S., Europe, and Japan, Insmed estimates the addressed patient population at 500,000, 600,000, and 150,000 diagnosed patients, respectively.Approval was based on late- and mid-stage data, in which Brinsupri reduced annual flare-ups by 21.1% at the 10 mg dose and 19.4% at the 25 mg dose compared to placebo. Both doses also delayed the time to&nbsp;the first flare.&nbsp;Applications have already been filed in Europe and the U.K., with a submission in Japan planned for 2025. If cleared overseas, Insmed expects to launch in those markets starting in 2026.Wells Fargo’s Tiago Fauth raised his price target to $140 from $130 and maintained an ‘Overweight’ rating, noting that approval had been expected, but the higher-end pricing could help the drug reach a market worth over $5 billion.&nbsp;RBC Capital’s team raised its target to $138 from $120 and called the label “a best-case scenario,” noting that both doses were approved without major warnings, key trial endpoints were met, and there was no exacerbation cutoff. They see the U.S. market at $3.8 billion and the global opportunity topping $6 billion.Meanwhile, Bank of America stuck with its $121 target and ‘Buy’ rating, saying the label contained no surprises. While approval is a major milestone, the bank said the bigger question now is whether Insmed can deliver on its own $5 billion peak sales projection.On Stocktwits, retail sentiment for Insmed was ‘extremely bullish’ amid a 340% surge in 24-hour message volume.One user remarked that Insmed looked like a strong long-term hold, predicting a major growth phase ahead and noting that many patients have no alternatives. They added that with minimal side effects or warnings, the drug could more easily be used for other conditions.<stembedurl>https://stocktwits.com/InvestorWisdom/message/624897660</stembedurl>Another user called the FDA label “a thing of beauty,” saying it effectively doubled the addressable market for non-cystic fibrosis bronchiectasis.&nbsp;They described the decision as a “grand slam” for the company, suggesting it could take off further if upcoming BiRCH trial results confirm Brinsupri’s broader potential.<stembedurl>https://stocktwits.com/JoeB07/message/624878902</stembedurl>Insmed’s stock has risen 76.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.

Insmed (INSM) said on Tuesday that the U.S. Food and Drug Administration (FDA) has approved its Brinsupri drug in the treatment of non-cystic fibrosis bronchiectasis (NCFB).Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for NCFB, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.insmed.com/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease">said</a>. It is approved in adults as well as children aged 12 years and older.<a href="https://stocktwits.com/symbol/INSM">INSM</a> stock jumped 4% on Tuesday afternoon following the news. On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Bronchiectasis is a serious, chronic lung disease that causes airways to permanently widen due to a cycle of infection, inflammation, and lung tissue damage. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. A hallmark of bronchiectasis is frequent exacerbations, or flares, when symptoms worsen.Most cases of Bronchiectasis in adults are non-cystic fibrosis bronchiectasis, Insmed noted. According to the company, about 500,000 patients in the U.S., 600,000 patients in France, Germany, Italy, Spain, and the U.K., and 150,000 patients in Japan have been diagnosed with NCFB.Brinsupri’s FDA approval is based on data from a late-stage and mid-stage trial. In the late-stage study, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also significantly prolonged the time to first exacerbation.Insmed said that its applications for the drug with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file for approval in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory, it added.INSM stock is up by 70% this year and by about 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-in-spotlight-as-fda-reportedly-mulls-withdrawing-authorization-for-covid-vaccine-for-kids-under-5/chrxIiKRdJL">Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease

Brinsupri, an oral, once-daily treatment, is now the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis, the company said.

Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock

Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM
Insmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INSM News

INSM Insmed Inc